Ketorolac

Mechanism

Ketorolac is the most potent oral and parenteral NSAID. Aspirin irreversibly blocks platelet cyclooxygenase. Co-administration of two NSAIDs adds up the risks: gastrointestinal bleeding, acute kidney injury, sodium and fluid retention. FDA Toradol Section 4.3 specifically lists aspirin and other NSAIDs as contraindications.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Acute kidney injury and a rise in blood pressure are also possible. Risk of bleeding multiplies in patients over 65 and with prior peptic ulcer disease.

Management

The combination is not prescribed. If aspirin is required for cardioprotection (75–100 mg/day), replace ketorolac with paracetamol, metamizole, or a short opioid course. Ketorolac courses are limited to 5 days under all circumstances.

Mechanism

Ketorolac outweighs other NSAIDs in antiplatelet and ulcerogenic effect. Its label places treatment with aspirin or other NSAIDs, selective COX-2 inhibitors included, among the contraindications, and the interactions section states it must not be used with other NSAIDs because of the increased rate of serious class adverse effects: gastrointestinal bleeding and perforation, renal injury, and bleeding from platelet inhibition. Analgesia does not improve when the second drug is added, since the target is the same enzyme family – cyclooxygenase.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain, sudden weakness and pallor from anaemia. Falling urine output and swelling as a sign of renal injury. In older people and those with a history of ulcer the picture may begin with the bleed itself, without preceding pain.

Management

The combination is taken apart: one NSAID remains. For severe pain that is usually ketorolac in a short course within the label limit, with the rest of the analgesia covered by paracetamol, metamizole or an opioid. Gastroprotection with a proton pump inhibitor does not lift the contraindication. After a ketorolac dose, another NSAID is not added until its action ends, not merely until the next scheduled dose.

Mechanism

Ketorolac and diclofenac are both NSAIDs. Co-administration adds up the risks: gastrointestinal bleeding, acute kidney injury, raised blood pressure. FDA Toradol Section 4.3 specifically lists other NSAIDs as contraindications.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Acute kidney injury and a rise in blood pressure are also possible. Risk of bleeding multiplies in patients over 65 and with prior peptic ulcer disease.

Management

The combination is not prescribed. For adequate analgesia, choose one NSAID as monotherapy (diclofenac or ketorolac short course with PPI cover such as pantoprazole). Alternative: paracetamol plus an opioid if pain is insufficiently controlled.

Mechanism

Ketorolac and ibuprofen are both NSAIDs. Additive risk of gastrointestinal bleeding, acute kidney injury, and blood pressure dysregulation. FDA Toradol Section 4.3 specifically lists other NSAIDs as contraindications.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Acute kidney injury and a rise in blood pressure are also possible. Risk of bleeding multiplies in patients over 65 and with prior peptic ulcer disease.

Management

The combination is not prescribed. One NSAID at a time. Ketorolac courses are limited to 5 days. If analgesia from one NSAID is insufficient, add paracetamol or a short opioid – not a second NSAID.

Mechanism

Ketorolac outweighs other NSAIDs in antiplatelet and ulcerogenic effect. Its label places treatment with aspirin or other NSAIDs, selective COX-2 inhibitors included, among the contraindications, and the interactions section states it must not be used with other NSAIDs because of the increased rate of serious class adverse effects: gastrointestinal bleeding and perforation, renal injury, and bleeding from platelet inhibition. Analgesia does not improve when the second drug is added, since the target is the same enzyme family – cyclooxygenase.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain, sudden weakness and pallor from anaemia. Falling urine output and swelling as a sign of renal injury. In older people and those with a history of ulcer the picture may begin with the bleed itself, without preceding pain.

Management

The combination is taken apart: one NSAID remains. For severe pain that is usually ketorolac in a short course within the label limit, with the rest of the analgesia covered by paracetamol, metamizole or an opioid. Gastroprotection with a proton pump inhibitor does not lift the contraindication. After a ketorolac dose, another NSAID is not added until its action ends, not merely until the next scheduled dose.

Mechanism

Ketorolac outweighs other NSAIDs in antiplatelet and ulcerogenic effect. Its label places treatment with aspirin or other NSAIDs, selective COX-2 inhibitors included, among the contraindications, and the interactions section states it must not be used with other NSAIDs because of the increased rate of serious class adverse effects: gastrointestinal bleeding and perforation, renal injury, and bleeding from platelet inhibition. Analgesia does not improve when the second drug is added, since the target is the same enzyme family – cyclooxygenase.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain, sudden weakness and pallor from anaemia. Falling urine output and swelling as a sign of renal injury. In older people and those with a history of ulcer the picture may begin with the bleed itself, without preceding pain.

Management

The combination is taken apart: one NSAID remains. For severe pain that is usually ketorolac in a short course within the label limit, with the rest of the analgesia covered by paracetamol, metamizole or an opioid. Gastroprotection with a proton pump inhibitor does not lift the contraindication. After a ketorolac dose, another NSAID is not added until its action ends, not merely until the next scheduled dose.

Mechanism

Ketorolac is a potent non-selective NSAID; nimesulide is a selective COX-2 inhibitor. Despite different selectivity, gastrointestinal and renal effects are additive. FDA Toradol Section 4.3 specifically lists all NSAIDs as contraindications.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Acute kidney injury and a rise in blood pressure are also possible. Risk of bleeding multiplies in patients over 65 and with prior peptic ulcer disease.

Management

The combination is not prescribed. Use one NSAID at the minimum effective dose with PPI cover (pantoprazole). Alternative: paracetamol as baseline analgesia.

Mechanism

Ketorolac inhibits platelet aggregation, prolongs bleeding time and damages the gastric mucosa; according to its SmPC it causes serious gastrointestinal toxicity more often than equivalent doses of other NSAIDs. NSAIDs enhance the effect of coumarin anticoagulants such as warfarin on bleeding time, and patients taking warfarin with an NSAID have a higher risk of serious gastrointestinal bleeding than with either drug alone.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

The combination is contraindicated: Spanish ketorolac SmPCs (10 mg tablets, 30 mg/ml injection) contraindicate ketorolac in patients on coumarin anticoagulants, and warfarin is one of them (ketorolac SmPCs). The originator SmPC (Toradol) lists anticoagulants among combinations that are not recommended and asks for maximum caution with warfarin (Toradol SmPC). The FDA allows such therapy only with extreme caution, after weighing benefits against risks and with close monitoring (US ketorolac label). If the patient has already received ketorolac, stop it at once if gastrointestinal bleeding is suspected (ketorolac SmPCs); whenever a drug is started or stopped in a patient on warfarin, monitor the INR closely (warfarin SmPC).

Mechanism

Ketorolac inhibits platelet aggregation, prolongs bleeding time and damages the gastric mucosa; according to its SmPC it causes serious gastrointestinal toxicity more often than equivalent doses of other NSAIDs. Apixaban is a direct factor Xa inhibitor, and its SmPC notes that NSAIDs usually increase bleeding risk, so the risks add up.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Spanish ketorolac SmPCs list anticoagulants among combinations that are not recommended, and for patients on full (therapeutic) doses of anticoagulants the interaction section calls the combination contraindicated (ketorolac 10 mg and 30 mg/ml SmPCs). Ketorolac is therefore not given to patients on a therapeutic dose of apixaban. At any anticoagulant dose, the FDA allows the combination only after weighing benefits against risks, with extreme caution and close monitoring (US ketorolac label). The apixaban SmPC asks for caution when it is combined with NSAIDs (apixaban SmPC, EMA), and the US apixaban label asks doctors to explain the signs of blood loss and to tell patients to report them at once (US apixaban label). In older patients and those at high risk of gastrointestinal complications, start ketorolac at the lowest dose and consider gastroprotection with misoprostol or a proton pump inhibitor; oral treatment lasts no more than 7 days (ketorolac 10 mg SmPC). Stop ketorolac at once if bleeding is suspected (ketorolac SmPCs).

Mechanism

Additive nephrotoxicity. Ketorolac (NSAID) suppresses prostaglandin-dependent renal blood flow; iodinated contrast (iopromide) adds osmotic load. High risk of acute kidney injury.

Symptoms

Reduced urine output, rising creatinine, proteinuria. Severe cases include oliguria and need for haemodialysis. Symptoms appear 1–3 days after contrast.

Management

Stop ketorolac 48 hours before planned contrast and resume 48 hours after with stable renal function. Alternative analgesics: paracetamol, metamizole, or a short opioid course. Provide contrast nephroprotection with adequate saline hydration.

Mechanism

Ketorolac reduces renal methotrexate clearance and suppresses tubular secretion. At high oncologic methotrexate doses: risk of severe toxicity (pancytopenia, nephrotoxicity, mucositis).

Symptoms

Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

At oncologic methotrexate doses, the combination is not prescribed. At low rheumatologic doses, avoid ketorolac; use paracetamol or a short opioid course for analgesia. Ketorolac courses never exceed 5 days.

Mechanism

Ketorolac inhibits platelet aggregation, prolongs bleeding time and damages the gastric mucosa; according to its SmPC it causes serious gastrointestinal toxicity more often than equivalent doses of other NSAIDs. Rivaroxaban is a direct factor Xa inhibitor, and its SmPC notes that NSAIDs increase bleeding risk on their own, so the risks add up.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Risk is higher in older patients and with a history of peptic ulcer disease.

Management

Spanish ketorolac SmPCs list anticoagulants among combinations that are not recommended, and for patients on full (therapeutic) doses of anticoagulants the interaction section calls the combination contraindicated (ketorolac 10 mg and 30 mg/ml SmPCs). Ketorolac is therefore not given to patients on a therapeutic dose of rivaroxaban. At any anticoagulant dose, the FDA allows the combination only after weighing benefits against risks, with extreme caution and close monitoring (US ketorolac label). The rivaroxaban SmPC asks for caution with any NSAID and allows ulcer prophylaxis in patients at risk of peptic ulcer disease (rivaroxaban SmPC, EMA). In older patients and those at high risk of gastrointestinal complications, start ketorolac at the lowest dose and consider gastroprotection with misoprostol or a proton pump inhibitor; oral treatment lasts no more than 7 days (ketorolac 10 mg SmPC). Stop ketorolac at once if bleeding is suspected (ketorolac SmPCs).

Mechanism

Ketorolac is the most nephrotoxic NSAID, limited to 5 days of use. Tacrolimus is nephrotoxic in its own right. Additive acute kidney injury risk multiplies in transplant patients.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

The combination is not prescribed. For post-transplant analgesia: paracetamol (up to 2 g/day), metamizole, or a short opioid course. For neuropathic pain: gabapentin or pregabalin.

Mechanism

Ketorolac suppresses vasodilator prostaglandins, weakening amlodipine's antihypertensive effect. Plus additive nephrotoxicity.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting the NSAID. In chronic kidney disease: risk of fluid retention and oedema.

Management

Ketorolac courses are limited to 5 days. Monitor blood pressure and creatinine in the first days. In chronic kidney disease or reduced ejection fraction, avoid ketorolac; use paracetamol or a short opioid course for analgesia.

Mechanism

NSAIDs weaken the antihypertensive effect of beta-blockers via prostaglandin-dependent renal regulation (natriuresis). Ketorolac is the most potent NSAID.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting the NSAID. In chronic kidney disease: risk of fluid retention and oedema.

Management

Ketorolac courses are limited to 5 days. Check blood pressure in the first days. In borderline hypertension, temporarily increase bisoprolol. For chronic analgesia: paracetamol or a short opioid course.

Mechanism

Glucocorticoid plus NSAID — additive risk of GI ulcers and bleeding. Systemic budesonide (Cortiment, Entocort) raises risk; inhaled budesonide does not.

Symptoms

Epigastric pain, heartburn, black or tarry stools, blood in vomit, bruising. Higher risk in older patients, prior peptic ulcer, and concurrent anticoagulants.

Management

Ketorolac is not prescribed with systemic budesonide — risk outweighs benefit. For acute pain: paracetamol up to 3 g/day or metamizole. If NSAIDs are necessary (short course in cancer or postoperative pain), add pantoprazole 20 mg/day and cap ketorolac at 5 days. Inhaled budesonide with NSAIDs is safe.

Mechanism

Ketorolac carries the highest digestive risk of the group and its label contraindicates it in patients on aspirin or other NSAIDs. Metamizole does not fall into that category, so the pair is not contraindicated, yet it stacks two different risks on the same patient: gastrointestinal bleeding from ketorolac and agranulocytosis from metamizole. The added analgesia is modest against that weight.

Symptoms

From ketorolac: black stools, coffee-ground vomit, epigastric pain, reduced urine output. From metamizole: returning fever, sore throat, mouth ulcers. The combination over 65 or with a prior ulcer concentrates both scenarios.

Management

The ketorolac course is short by label and admits no other NSAID alongside; metamizole may accompany it in severe acute pain, but it is worth checking whether paracetamol fills the gap first. Keep gastric protection while ketorolac lasts and watch the blood count if metamizole continues.